Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.

Saved in:
Bibliographic Details
Title: Safety and efficacy of the monoclonal antibody L9LS for malaria prevention in children exposed to perennial malaria transmission in Kenya: a randomised, double-blind, placebo-controlled, phase 2 trial.
Authors: Steinhardt LC; Malaria Branch, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA. Electronic address: LSteinhardt@cdc.gov., Kwambai TK; Malaria Branch, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Kisumu, Kenya., Oneko M; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Ouma E; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Njoroge R; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Callier V; Clinical Monitoring Research Program Directorate, Frederick National Laboratory, Frederick, MD, USA., Hu Z; Office of Biostatistics Research, Division of Clinical Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Gutman JR; Malaria Branch, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Yego R; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Otieno K; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Onoka K; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Otieno L; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Oduol K; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Serebryannyy L; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Lin BC; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Adams W; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Hickman S; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Preston AC; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Carlton K; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Holdsworth M; Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., Xiao Y; Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA., O Ter Kuile F; Department of Clinical Sciences, Liverpool School of Tropical Medicine, Liverpool, UK., Odongo W; Malaria Branch, National Center for Emerging and Zoonotic Infectious Diseases, US Centers for Disease Control and Prevention, Atlanta, GA, USA., Murphy SC; Malaria Molecular Diagnostic Laboratory, Department of Laboratory Medicine and Pathology, and the Center for Emerging and Re-emerging Infectious Diseases, University of Washington, Seattle, WA, USA., Tran TM; Division of Infectious Diseases, Department of Medicine and Ryan White Center for Pediatric Infectious Disease and Global Health, Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN, USA., Kariuki S; Kenya Medical Research Institute, Global Health Research Centre, Kisumu, Kenya., Crompton PD; Malaria Infection Biology and Immunity Section, Laboratory of Immunogenetics, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Rockville, MD, USA. Electronic address: pcrompton@niaid.nih.gov., Seder RA; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.
Corporate Authors: Kenya Malaria mAb Trials Team
Source: Lancet (London, England) [Lancet] 2026 Apr 25; Vol. 407 (10539), pp. 1614-1625.
Publication Type: Journal Article; Randomized Controlled Trial; Clinical Trial, Phase II
Journal Info: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1474-547X
DOI:10.1016/S0140-6736(26)00258-8